H.C. Wainwright Downgrades Aviragen Therapeutics (AVIR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Ladenburg Thalmann Downgrades Aviragen (AVIR) to Neutral
February 14, 2017 8:30 AM ESTLadenburg Thalmann downgraded Aviragen (NASDAQ: AVIR) from Buy to Neutral.
For an analyst ratings summary and ratings history on Aviragen click here. For more ratings news on Aviragen click here.
Shares of Aviragen closed at $1.08 yesterday.
... MoreAviragen Therapeutics' (AVIR) Phase 2b SPIRITUS Trial of Vapendavir Fails
February 13, 2017 4:02 PM ESTAviragen Therapeutics (NASDAQ: AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection. Vapendavir did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 (ACQ-6) at day 14, the primary endpoint, for either the 264 mg or 528 mg cohorts compared to placebo.
We are disappointed that the... More
